

# Chapter 10:

Calcium Gluconate, Calcium Chloride, and Hypertonic Dextrose Solutions



To get a copy of the book, visit: www.fluidtherapy.org



# **10** Calcium Gluconate, Calcium Chloride, and Hypertonic Dextrose Solutions

# CALCIUM GLUCONATE AND CALCIUM CHLORIDE 116 Composition 116 Pharmacological basis 116 Indications 116 Hyperkalemia 116 Hypocalcemia 117 Severe hypermagnesemia 117 Calcium-channel blocker 118 β-blocker overdose 118 Prevent citrate toxicity 118

Contraindications and precautions11	9
Cardiac resuscitation11	9
Hydrofluoric acid burns11	9

### HYPERTONIC DEXTROSE

SOLUTIONS	120
Composition	120
Pharmacological basis	120
Indications	120
Contraindications	120
Adverse effects and cautions	120

Commonly used special solutions are calcium chloride, calcium gluconate, dextrose 25% and 50%, hypertonic

saline, magnesium sulfate, potassium chloride, potassium phosphate, and sodium bicarbonate (Table 10.1).

Table 10.1 Composition of commonly used special solutions						
Injection	Content in mEq/ml	Volume of amp (mL)	Content in mEq/amp	gm/10 ml amp		
Calcium gluconate 10%	$Ca^{2+} = 0.45$	10	Ca <sup>2+</sup> = 4.5/10 ml	1.0		
Calcium chloride 10%	$Ca^{2+} = 1.36$	10	Ca <sup>2+</sup> = 13.6/10 ml	1.0		
Hypertonic (3%) saline	Na <sup>+</sup> = 0.5	100	Na+ = 51/100 ml	3.0		
Magnesium sulfate 50%	$Mg^{2+} = 4$	2.0	Mg <sup>2+</sup> = 8/2 ml	1.0		
Potassium chloride 15%	K <sup>+</sup> = 2.0	10	K <sup>+</sup> = 20/10 ml	1.5		
Potassium phosphates	$K^+ = 4.4$ $PH_4 = 3.0$	15	K+ = 66/15 ml PH <sub>4</sub> = 45/15 ml	-		
7.5% NaHCO <sub>3</sub>	$HCO_{3} = 0.9$	10	HCO <sub>3</sub> = 9/10 ml	0.75		
8.4% NaHCO <sub>3</sub>	$HCO_{3} = 1.0$	20	HCO <sub>3</sub> = 10/10 ml	0.84		
HCO <sub>3</sub> : Bicarbonate; Ca <sup>2+</sup> : Calcium; Mg <sup>2+</sup> : Magnesium; PH <sub>4</sub> : Phosphate; K <sup>+</sup> : Potassium; Na <sup>+</sup> : Sodium; NaHCO <sub>3</sub> : Sodium bicarbonate						

### To get a copy of the book, visit: www.fluidtherapy.org



### INJECTION CALCIUM GLUCONATE AND CALCIUM CHLORIDE

ride are two different salt forms commonly used in various emergency conditions.

Inj. calcium gluconate and calcium chlo-

## Want to read more?

**Get Printed Version** 

**Get Kindle Version** 

### REFERENCES

- Davey M, Caldicott D. Calcium salts in management of hyperkalaemia. Emerg Med J. 2002;19(1):92–3.
- Long B, Warix JR, Koyfman A. Controversies in Management of Hyperkalemia. J Emerg Med. 2018;55(2):192–205.
- 3. Semple P, Booth C. Calcium chloride; a reminder. Anaesthesia 1996;51(1):93.
- 4. Weisberg LS. Management of severe hyperkalemia. Crit Care Med 2008;36(12):3246–51.
- Truhlar A, Deakin CD, Soar J, et al., European resuscitation council guidelines for resuscitation 2015: Section 4. Cardiac arrest in special circumstances. Resuscitation, 2015;95:148–201.
- Batterink J, Cessford TA, Taylor RAI. Pharmacological interventions for the acute management of hyperkalaemia in adults. Cochrane Database of Systematic Reviews 2015;10:CD010344.
- 7. Robert T, Joseph A, Mesnard L. Calcium salt during hyperkalemia. Kidney Int. 2016;90(2):451–452.
- Wang CH, Huang CH, Chang WT, et al. The effects of calcium and sodium bicarbonate on severe hyperkalaemia during cardiopulmonary resuscitation: A retrospective cohort study of adult in-hospital cardiac arrest. Resuscitation,2016;98:105–11.
- 9. Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122:S829–S861.
- Helman A, Baimel M, Etchells E. Emergency management of hyperkalemia. Emergency Medicine Cases. 2016 https://emergencymedicinecases.com/ emergency-management-hyperkalemia/Accessed 11 June 2020.

- Ahee P, Crowe AV. The management of hyperkalaemia in the emergency department. J Accid Emerg Med. 2000;17(3):188–191.
- Cooper MS, Gittoes NJL. Diagnosis and management of hypocalcaemia. BMJ 2008;336(7656):1298–1302.
- Walsh J, Gittoes N, Selby P. Society for Endocrinology Endocrine Emergency Guidance: Emergency management of acute hypocalcemia in adult patients. Endocr Connect. 2016;5(5):G9–G11.
- Rietjens SJ, de Lange DW, Donker DW, et al. Practical recommendations for calcium channel antagonist poisoning. Neth J Med 2016;74(2):60–67.
- Graudins A, Lee H, Druda D. Calcium channel antagonist and beta-blocker overdose: Antidotes and adjunct therapies. Br J Clin Pharmacol 2016;81(3):453–461.
- St-Onge M, Anseeuw K, Cantrell FL, et al. Experts consensus recommendations for the management of calcium channel blockerpoisoning in adults. Crit Care Med. 2017;45(3):e306–e315.
- 17. Kumar K, Biyyam M, Bajantri B, et al. Critical management of severe hypotension caused by amlodipine toxicity managed with hyperinsulinemia/ euglycemia therapy supplemented with calcium gluconate, intravenous glucagon and other vasopressor support: Review of literature. Cardiol Res 2018;9(1):46–49.
- Shah SK, Goswami SK, Babu RV, et al. Management of calcium channel antagonist overdose with hyperinsulinemia-euglycemia therapy: case series and review of the literature. Case Rep Crit Care. 2012;2012:927040.
- Lima SK, Begum M, Gupta AK, et al. Management of Massive Blood Transfusion-a case study. Pulse 2014;5(1):39–43.



- Hess JR, Silvergleid AJ. Massive blood transfusion. In: Post TW, editor. UpToDate. Waltham, MA: Wolters Kluwer Health. http://www.uptodate.com. Accessed 12 Sept 2020.
- Basic-Jukic N, Kes P, Glavas-Boras S, et al. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial. 2005;9(5):391–5.
- 22. Lee G, Arepally GM. Anticoagulation techniques in apheresis: from heparin to citrate and beyond. J Clin Apher. 2012;27(3):117–125.
- Sigler K, Lee J, Srivaths P. Regional citrate anticoagulation with calcium replacement in pediatric apheresis. J Clin Apher. 2018;33(3):274–7.
- 24. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25(3):83–177
- Patterson ER, Winters JL. Hemapheresis. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods E-Book. (23rd ed., pp. 779) St Louis, MO: Elsevier;2017.
- Weinstein R. Prevention of citrate reactions during therapeutic plasma exchange by constant infusion of calcium gluconate with the return fluid. J Clin Apher. 1996;11(4):204–210.
- Kankirawatana S, Huang ST, Marques MB. Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange. J Clin Apher. 2007;22(5):265–269.
- Krishnan RG, Coulthard MG. Minimising changes in plasma calcium and magnesium concentrations during plasmapheresis. Pediatr Nephroly 2007;22(10):1763–1766.
- Section 5: Dialysis Interventions for Treatment of AKI. Kidney Int Suppl (2011). 2012;2(1):89–115.
- Oudemans-van Straaten HM, Ostermann M. Benchto-bedside review: Citrate for continuous renal replacement therapy, from science to practice. Crit Care 2012;16(6):249.
- Kindgen-Milles D, Brandenburger T, Dimski T. Regional citrate anticoagulation for continuous renal replacement therapy. Curr Opin Crit Care. 2018;24(6):450–4.
- 32. Karkar A, Ronco C. Prescription of CRRT: a pathway to optimize therapy. Ann. Intensive Care 2020;10(1):32.

- 33. Wu MY, Hsu YH, Bai CH, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: A metaanalysis of randomized controlled trials. Am J Kidney Dis 2012;59(6):810–818.
- 34. Stucker F, Ponte B, Tataw J, et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Crit Care 2015;19(1):91.
- 35. Liu C, Mao Z, Kang H, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a metaanalysis with trial sequential analysis of randomized controlled trials. Crit Care. 2016;20(1):144.
- Davenport A, Tolwani A. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. NDT Plus. 2009;2(6):439–447.
- 37. Morabito S, Pistolesi V, Tritapepe L, et al. Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit Care. 2012;16(3):R111.
- McKee D, Thoma A, Bailey K, et al. A review of hydrofluoric acid burn management. Plast Surg (Oakv). 2014;22(2):95–98.
- 39. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 6: pharmacology II: agents to optimize cardiac output and blood pressure. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation. 2000;102(8 Suppl):I129–135.
- Australian Resuscitation Council. Section 11 Adult advanced life support. ANZCOR Guideline 11.5 – Medications in Adult Cardiac Arrest August 2016 Available: https://resus.org.au/guidelines/.
- Morrison LJ, Deakin CD, Morley PT, et al. Part 8: Advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2010;122(16 Suppl 2):S345–421.
- 42. Gin A, Walker S. Notice to Hospitals regarding Ceftriaxone-calcium incompatibility: What's a clinician to do? Can J Hosp Pharm. 2009;62(2):157–8.

